Moderna shares fell as much as 25% on Thursday after partial data from its cancer vaccine developed with Merck leaked ahead of the full results, which were released later that day. The full data appeared positive relative to Wall Street expectations: the personalized vaccine intismeran autogene, combined with Keytruda, reduced the risk of recurrence or death in certain melanoma patients by 42% versus Keytruda alone, and cut the risk of distant spread or death by 38%. Detailed phase 3 results will be presented at the European Society for Medical Oncology conference this weekend. Investors view the vaccine as a possible breakthrough that could extend to other cancers, and the stock has spiked more than 530% this year on high expectations.
Summary written by Upside AI from the original article. Read the source for full details.
Keywords
healthcarecancer vaccinepharmaceuticalsModerna
Open a keyword to see other news on the same topic.
Related news
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice
- Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
BioNTech had 16.6 billion euros in cash, cash equivalents and securities at the end of the second quarter and has announced a share buyback of up to $1 billion. Its only commercialized product is Comirnaty, the COVID-19 vaccine it developed and markets with Pfizer, while it aims to become a multiproduct oncology company by 2030. Its pipeline includes 14 ongoing pivotal trials and more than 10 novel combination approaches, with pumitamig, developed with Bristol Myers Squibb, showing encouraging lung cancer results with chemotherapy and being tested in seven pivotal trials under the ROSETTA program. Of the 20 analysts covering the stock, 13 rate it a strong buy and the rest a hold, with target prices implying potential upside of 5% to 64%. The stock trades at a price-to-sales ratio of 7, but risks include trial failures, regulatory delays, competition and declining COVID-19 vaccine revenue.
- Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Moderna shares fell 10% to $214.03 in morning trading as investors took profits after a steep rally tied to its personalized cancer vaccine. In August, Moderna said intismeran autogene, given with Keytruda, met its primary endpoint in a late-stage melanoma trial, sending the stock to its best single-day gain ever. Five-year follow-up from a Phase 2b study showed the combination cut the risk of recurrence or death by 49% versus Keytruda alone. Meanwhile, BioNTech fell 2%, Pfizer rose 0.3%, the iShares Biotechnology ETF slid 2% and the S&P 500 ETF (SPY) dipped 0.1%, pointing to selling concentrated in Moderna. Goldman Sachs raised its price target but kept a Neutral rating, with full melanoma data due at ESMO later this month.
- Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
Moderna shares rose 6% to $239.74 in afternoon trading, far outpacing peers BioNTech (NASDAQ:BNTX), up 2% to $90.10, and Pfizer (NYSE:PFE), up 2% to $29.65. The article links the move to money rotating out of AI and technology stocks into healthcare, with the iShares Biotechnology ETF (NASDAQ:IBB) up 3% to $208.35 while the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) was flat at $769.61. Moderna's outsized gain may also reflect an August late-stage melanoma trial, in which its personalized mRNA cancer vaccine given with Merck's Keytruda beat Keytruda alone. The article says fuller trial data is needed to confirm that story.
Related markets
Latest news
- SpaceX Says It’s on Pace to Bring 200,000 Nvidia Chips Online a Month. Here’s Why Jensen Huang Calls GPU-Backed Loans “the Big Idea”
Nvidia (NVDA) closed at $221.97 on October 21, up 2.54%, a day after SpaceX said on its earnings call it expects to bring about 200,000 Nvidia GB300s online each month for the rest of the year. According to the Financial Times, SpaceX is seeking about $40 billion in loans and investment-grade debt to buy the chips, with Apollo expected to lead; a source told CNBC the deal would likely use the GPUs as collateral, though Bloomberg reports talks are early and could fail. Nvidia is both a supplier and a SpaceX shareholder, with a stake worth about $21 billion at the end of June. The article's main risk is financing: if rental rates fall, collateral value falls too, and Nvidia's free cash flow dropped to $21.40 billion in the July quarter from $48.59 billion the prior quarter.
- a16z Drops Crypto From Its Name, Widens Bets to AI and Frontier Tech
Andreessen Horowitz is renaming its crypto fund “a16z Frontier” and widening its mandate to AI and other long-horizon technologies, according to an email to newsletter subscribers. The firm says it will keep investing in crypto and advocating for sensible crypto regulation. Chris Dixon argues blockchains have faded into the background of products from Wall Street and fintech firms, so companies should be defined by what they do rather than the technology they use. He expects new “native use cases” to emerge, and sees crypto as a way for AI agents to pay each other. The new fund will be led by Dixon with Marc Andreessen, Ben Horowitz, Eddy Lazzarin and Guy Wuollet; the post gives no size for it, and the latest figure on record is the $2.2 billion announced in May.
- Dell Unveiled New AI Servers a Week After Barclays’ Downgrade. Here’s Where the Stock Could Go by 2031
Dell unveiled new AI Factory servers with NVIDIA at GTC Berlin on October 21, one week after Barclays downgraded the stock and cut its target to $574 from $603. Shares closed at $485.88, still below the $572.47 close of October 13. Barclays argues strong revenue mainly reflects memory costs passed on to customers, while CFO David Kennedy says new dense systems can replace 5 or 6 of those existing servers and supply will be tighter in 2027. Traditional servers and networking revenue rose 122% to $10.5 billion in the fiscal second quarter, and the AI server backlog stood at $95 billion as of July 31. TIKR's mid-case scenario puts the stock near $750 by January 31, 2031, about 54% higher, while Dell reports fiscal third-quarter results after the close on November 24.
- Elon Musk invests $1bn in CNN-owner Skydance
Elon Musk reportedly invested $1bn in Skydance, the newly formed company created through Paramount's $110bn takeover of Warner Bros, which owns CNN and CBS News, according to Semafor. Skydance carries net debt of roughly $80bn and is targeting $6bn in cost savings. The article says the investment repays a favour to Larry Ellison, who backed Musk's $1bn Twitter takeover in 2022. While the cash may ease pressure on Skydance's balance sheet, it could also fuel concerns about a right-wing media empire, as unions have accused CBS of editorial interference.
- Winklevoss PAC moves into Texas Senate race with $81K ad buy
Digital Freedom Fund, a super PAC launched in 2025 by Gemini co-founders Cameron and Tyler Winklevoss, spent more than $81,000 on direct mail backing Republican Ken Paxton and opposing Democrat James Talarico in the Texas Senate race. The PAC also spent in Ohio, bringing its support for Republican Jon Husted to about $7 million, and reported raising about $34 million as of Sept. 30. Prediction markets Kalshi and Polymarket heavily favored Democrats retaking the House and Senate in 2027, a result that would significantly affect the chances of passing the Digital Asset Market Clarity Act. Paxton had earlier benefited from $500,000 in ads funded by Fellowship PAC, which went through Nxum Group, co-founded by former Trump crypto adviser Bo Hines, and Nxum reportedly received $6.3 million in a deal with Tether.
- Why HubSpot Stock Rallied Today
HubSpot shares jumped as much as 7% on Thursday amid speculation about software sector M&A. Earlier this week Salesforce agreed to acquire Braze for $5.66 billion at a 58% premium, and the prior week CCC Intelligent Solutions and Varonis Systems agreed to deals at 44% and 52% premiums. Jefferies analyst Samad Samana sees the Braze deal as a possible spark for a takeover of Klaviyo and considers HubSpot an attractive private equity candidate, though he views a direct acquisition as unlikely. The article estimates a HubSpot deal, given its market cap above $13 billion and an average 51% premium, could cost around $20 billion, but stresses this is speculation.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.